Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 5Tumor-Agnostic 4Plasma cell 4Genitourinary 4Sarcoma 3Thoracic 2Lymphoid 2Other hematologic neoplasm 1Breast 1

Conditions

Multiple Myeloma 4Recurrence 1

Interventions

Dexamethasone 315Bortezomib 166Lenalidomide 132pomalidomide 113daratumumab 96carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × perifosine × Plasma cell × Clear all
NCT00375791 2018-02-28

Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma

AEterna Zentaris

Phase 2 Completed
67 enrolled
Plasma cell

Multiple Myeloma

NCT00401011 2018-02-23

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

AEterna Zentaris

Phase 1/2 Completed
84 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01002248 2018-02-09

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

AEterna Zentaris

Phase 3 Terminated
135 enrolled
Plasma cell

Multiple Myeloma

NCT00415064 2012-07-06

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

AEterna Zentaris

Phase 1 Completed
32 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡